Discrepancies in metabolomic biomarker identification from patient-derived lung cancer revealed by combined variation in data pre-treatment and imputation methods.
Hunter A MillerRamy EmamChip M LynchSamuel BockhorstHermann B FrieboesPublished in: Metabolomics : Official journal of the Metabolomic Society (2021)
The combined choice of pre-treatment and imputation methods may need careful evaluation prior to metabolomic data analysis of human tumors, in order to enable consistent identification of potential biomarkers predictive of response to therapy and of disease stage.